High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register.

The aim of this study was to evaluate the clinical outcomes of etanercept in rheumatoid arthritis (RA) patients with moderate or severe disease activity. We analyzed data from the Italian biologics register Gruppo Italiano Studio Early Arthritides (GISEA) to investigate the rate of disease remission and functional improvement, based on the 28-Joint Disease Activity Score (DAS28) and the (Health Assessment Questionnaire (HAQ) score in RA patients with moderate or severe disease activity beginning etanercept therapy. Disease was defined as severe (H-RA) with DAS28 ≥5.1 and moderate (M-RA) with DAS28 ≥3.2 to 5.1 at baseline. Patients were considered in remission if DAS28 was ≤2.6, and HAQ ≤0.5 defined normal function. We enrolled 953 RA patients, 320 with M-RA and 633 H-RA. Age and disease duration were similar in the two cohorts, but H-RA patients had significantly more comorbidities (p < 0.01) and took significantly more disease-modifying antirheumatic drugs (p < 0.001) than M-RA patients. After 1 year, the percentage of patients achieving disease remission and normal function (DAS28 ≤2.6 plus HAQ ≤0.5) was higher in M-RA (21.4 %) than in H-RA patients (14.8 %, p = 0.007), regardless of the disease duration. Additionally, female gender (p = 0.006) and H-RA class (p = 0.002) negatively predicted disease remission at 1 year. However, the drug survival rate did not differ between the two subsets. This study confirms that etanercept was effective in the treatment of active RA, but best response, in terms of disease remission and normal function ability, was greater and easier to attain in M-RA patients. These findings may aid clinicians to choose the best strategy to treat RA.
AuthorsFlorenzo Iannone, Elisa Gremese, Gaia Gallo, Piercarlo Sarzi-Puttini, Costantino Botsios, Francesco Trotta, Stefania Gasperini, Mauro Galeazzi, Silvano Adami, Fabrizio Cantini, Marco Sebastiani, Roberto Gorla, Antonio Marchesoni, Annarita Giardina, Rosario Foti, Angiola Mele, Eleonora Bruschi, Gianluca Bagnato, Gian Luca Erre, Giovanni Lapadula,
JournalClinical rheumatology (Clin Rheumatol) Vol. 33 Issue 1 Pg. 31-7 (Jan 2014) ISSN: 1434-9949 [Electronic] Germany
PMID23954923 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antirheumatic Agents
  • Biological Products
  • Glucocorticoids
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Etanercept
  • Methotrexate
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antirheumatic Agents (administration & dosage)
  • Arthritis, Rheumatoid (drug therapy)
  • Biological Products (administration & dosage)
  • Drug Therapy, Combination
  • Etanercept
  • Female
  • Glucocorticoids (administration & dosage)
  • Humans
  • Immunoglobulin G (administration & dosage)
  • Italy
  • Male
  • Methotrexate (administration & dosage)
  • Middle Aged
  • Prospective Studies
  • Receptors, Tumor Necrosis Factor (administration & dosage)
  • Registries
  • Remission Induction
  • Severity of Illness Index
  • Surveys and Questionnaires
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha (antagonists & inhibitors)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: